Volume 28, Number 5—May 2022
Research
Determining Existing Human Population Immunity as Part of Assessing Influenza Pandemic Risk
Table 1
Virus | Virus abbreviation | Virus lineage | No. (%) persons |
GMT | |
---|---|---|---|---|---|
Seroprevalence ≥40 | Seroprevalence ≥10 | ||||
A/swine/HK/NS4003/2016 (H1N1) | NS4003 | EA | 34 (9.6) | 105 (29.7) | 7.67 |
A/swine/GD/104/2013 (H1N1) | GD104 | EA | 39 (11.0) | 89 (25.2) | 7.84 |
A/swine/HK/NS301/2013 (H1N2) | NS301 | TRIG | 27 (7.6) | 115 (32.6) | 7.76 |
A/swine/HK/1436/2016 (H1N1) | TS1436 | Pandemic (pdm09) | 146 (41.4) | 222 (62.9) | 20.96 |
A/swine/HK/4348/2016 (H3N2) | TS4348 | Seasonal (BD-like H3) | 239 (67.7) | 308 (87.3) | 48.77 |
*Serum samples were collected during 2013–2014 in Hong Kong and during 2015 in Guangzhou. BD, Binh Duong; EA, Eurasian avian-like; GMT, geometric mean titer; TRIG, triple-reassortant internal gene.
Page created: February 24, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.